ValuEngine Upgrades Evofem Biosciences (EVFM) to “Sell”

Evofem Biosciences (NASDAQ:EVFM) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

EVFM has been the subject of several other research reports. BTIG Research reissued a “hold” rating on shares of Evofem Biosciences in a research note on Tuesday, March 20th. HC Wainwright assumed coverage on shares of Evofem Biosciences in a research note on Monday, March 19th. They issued a “buy” rating and a $15.00 price target for the company.

How to Become a New Pot Stock Millionaire

EVFM stock remained flat at $$6.20 during mid-day trading on Wednesday. 101 shares of the company’s stock were exchanged, compared to its average volume of 19,679. Evofem Biosciences has a 12 month low of $1.80 and a 12 month high of $15.78.

COPYRIGHT VIOLATION NOTICE: “ValuEngine Upgrades Evofem Biosciences (EVFM) to “Sell”” was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3335040/valuengine-upgrades-evofem-biosciences-evfm-to-sell.html.

Evofem Biosciences Company Profile

Evofem Biosciences, Inc develops therapeutic solutions to meet sexual and reproductive health needs of women. The company's product includes, Amphora contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections, and antimicrobial drug product to prevent the reoccurrence of bacterial vaginosis.

Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Matador Resources  versus Callitas Health  Head-To-Head Comparison
Matador Resources versus Callitas Health Head-To-Head Comparison
Cousins Properties  Earns Market Perform Rating from Analysts at Wells Fargo
Cousins Properties Earns Market Perform Rating from Analysts at Wells Fargo
$63.31 Million in Sales Expected for First Bancorp  This Quarter
$63.31 Million in Sales Expected for First Bancorp This Quarter
Royal Bank of Canada Reaffirms “Hold” Rating for BancorpSouth Bank
Royal Bank of Canada Reaffirms “Hold” Rating for BancorpSouth Bank
Morgan Stanley Raises Continental Resources  Price Target to $77.00
Morgan Stanley Raises Continental Resources Price Target to $77.00
Morgan Stanley Lowers Cabot Oil & Gas  Price Target to $31.00
Morgan Stanley Lowers Cabot Oil & Gas Price Target to $31.00


© 2006-2018 Ticker Report. Google+.